Tscan Therapeutics
Open
$0.93
Prev. Close
$0.93
High
$0.93
Low
$0.92
Market Snapshot
$51.9M
-0.4
-1.15
$2.82M
139
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 142 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 142 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The firm is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The firm builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Recently from Cashu
Tscan Therapeutics Leverages AI to Transform Immunotherapy and Accelerate Drug Development
Tscan Therapeutics Embraces AI-Driven Innovations in Therapeutic Development Tscan Therapeutics, a leader in the field of immunotherapy, is increasingly recognizing the transformative potential of art…
AI Revolutionizes Content Creation for Tscan Therapeutics in Biotechnology and Therapeutics
Harnessing AI for Enhanced Content Creation in the Therapeutics Industry Tscan Therapeutics operates at the intersection of biotechnology and innovation, where the integration of artificial intelligen…